Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
BRACAnalysis developer reports results for first quarter of fiscal 2003
December 26th, 2002
Myriad Genetics, Inc., (MYGN) reported that for the 3-month period ended September 30, 2002, predictive medicine revenues increased to $7.9 million from $5.5 million in the same quarter last year, an increase of 43%. Gross margins on the predictive medicine business reached a new high of 63% for the quarter, an improvement from 59% in the first quarter of fiscal 2002. As of September 30, 2002, Myriad had approximately $104 million in cash and investments. The increase resulted primarily from steadily increasing sales of the BRACAnalysis predictive medicine product for breast and ovarian cancer and accelerating growth in the COLARIS and COLARIS AP...
Source: Women's Health Weekly (2002-12-26)
|
